Healthcare industry

Nitec Pharma AG, a spin-off from Merck (Darmstadt, Germany) and Horizon Therapeutics, Inc. (USA) have announced the combination of their businesses to become Horizon Pharma, Inc. and the filing of a registration statement for a proposed initial public offering. The company’s Mannheim-based subsidiary, which is focused on the development and commercialisation of drugs for the treatment of pain and chronic inflammatory diseases, has been named…

SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) announced today a comprehensive, strategic restructuring of the company, which will include significant personnel and cost reductions. The process has been approved by the Supervisory Board and will be executed immediately.

Vetter Pharma-Fertigung GmbH Co. KG have announced the establishment of a new subsidiairy Vetter Pharma International GmbH VPI. The launch is scheduled for April 1st 2009. Peter Sölkner will be the Managing Director and is one of three Vetter managers appointed since June 2008.

Vetter Pharma Fertigung GmbH Co has been granted approval by the American Food and Drug Administration FDA for the production of a new client drug. Vetter will now be filling injection systems with the new drug at its Ravensburg facility. Vetter has invested over 100 million euros.

Article - 16/04/2012

Pharma 2.0: towards paperless production

Before electronic solutions existed lorries were needed to ship new drug applications which often comprised 500000 or so pages. Thanks to IT this is no longer necessary. IT-based procedures and solutions are playing an increasing role in all areas of the pharmaceutical industry. Markus Roemer CEO of Ravensburg-based comes compliance services supports companies in implementing legal guidelines in this area. In the following interview Roemer talks…

Press release - 13/10/2009

Trenzyme receives ISO 9001 certification

The Trenzyme GmbH has set another milestone as a first class service provider for the pharma and life science industry.

Article - 24/10/2011

Ascendis Pharma: transient drug conjugates

Ascendis Pharma’s proprietary technology platform, TransCon, is a novel prodrug technology for the production of new patentable versions of drugs already on the market, which has been developed for improving the dosage form and effect in patients. A Phase II clinical study of Ascendis Pharma’s most advanced drug candidate, a PEGylated growth hormone that only needs to be administered once-weekly to growth hormone-deficient adults, has recently…

Press release - 26/03/2009

Sygnis Pharma AG increases capital

SYGNIS Pharma AG reported its financial results for the first nine months of the fiscal year 20082009. The company improved its cash position significantly as a result of a successful capital increase. Following the capital increase the stake of dievini Hopp BioTech in SYGNIS Pharma AG increased to approximately 44.90 of the total share capital. The preparations for the phase II efficacy trial of its lead candidate AX200 in acute ischemic stroke…

Press release - 22/10/2009

SYGNIS secures up to € 10 Million through a 3 year Standby Equity Distribution Agreement (SEDA) with Yorkville

SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard), a clinical stage biotech company developing innovative CNS treatments, today announced that it has entered into a 3 year standby equity distribution agreement (SEDA) with YA Global Master SPV LTD (YA Global) a fund managed by Yorkville Advisors, LLC located in New Jersey USA.

Lipid Therapeutics GmbH and Dr. Falk Pharma GmbH announced on 30th, September, that they have entered into a co-development and licensing agreement for LT-02. Under the terms of the agreement, Dr. Falk Pharma will receive exclusive access to the European rights to Lipid Therapeutics’ lead product LT-02 for the treatment of ulcerative colitis. Ulcerative colitis is a severe inflammation of the colon affecting more than one million people…

Press release - 13/08/2009

Sygnis published its financial results for the first quarter of 2009/2010

SYGNIS Pharma AG published its financial results for the first quarter of the fiscal year 2009/2010, which ended on 30 June 2009.

Article - 20/02/2012

Vektor-Pharma: a start-up that merges pharmacy and mechanical engineering

The company Vektor-Pharma plans to develop and manufacture medicated adhesive patches and therapeutic films. Pharmacists and mechanical engineers have entered into a kind of symbiotic relationship and are currently working on the establishment of a successful business. Interdisciplinary synergy is key to developing such transdermal therapeutic systems TTS more quickly effectively and cheaply than any one discipline would be able to do on its own.…

Article - 09/07/2012

Bachelor’s and master’s graduates – what really counts is individual aptitude

Ravensburg-based Vetter Pharma GmbH has been constantly growing over the last few years; the company took on 300 new staff in 2011 and plans to recruit 350 more in 2012. The company is desperately looking for qualified young people to help manage its growth. In what way does this impact on job opportunities for bachelor’s and master’s graduates? In the following interview, Christiane Priebe, Director of Human Resources at Vetter Pharma, talks…

Press release - 08/04/2010

Latest Trend: Investment-Fonds by Big Pharma

Boehringer Ingelheim announced the launch of its corporate venture capital fund the Boehringer Ingelheim Venture Fund BIVF. The BIVF aims to invest in Biotech and Start-up companies that provide ground-breaking therapeutic approaches and technologies to help drive innovation in medical science.

The CEOs of pharmaceutical and life science companies are becoming increasingly aware that their companies are facing growing challenges and risks at the global level. At the same time they are also aware of more and more opportunities.

Press release - 11/06/2010

comes compliance services enriches BioLAGO network

The addition of comes compliance services to the BioLAGO network broadens the life sciences associations skills in the fields of regulatory requirements and quality management systems. The company offers quality management systems audit services IT project management services quality risk management and validation services.

SYGNIS Pharma AG announced that it has received a positive recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency for AX200 in the treatment of spinal cord injury.

Article - 10/06/2009

Colleagues who became customers

Should they work with a long-standing cooperation partner or should they set up another company that was the decision faced by the staff of the Discovery-IT department of Nycomed formerly ALTANA Pharma in the spring of 2007.

Press release - 22/06/2011

SYGNIS Pharma AG secures further financial resources with shareholder loan

SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard) today executed a subordinated loan agreement for a total amount of EUR 6 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany (dievini), with an interest-rate at customary market conditions. As a result this loan, which is payable on demand, secures the financing of SYGNIS’ existing operations, according to the present plans, at…

Press release - 16/11/2010

Nycomed is keeping the pace in third quarter 2010 - US Food & Drug Administration to decide on the approval of Daxas®

Nycomed’s strategy of focusing on emerging markets and specialty products is paying off. The third quarter results shows that the sales of Key Products and in emerging markets are continuing to help offset the impact from the loss of exclusivity of pantoprazole. Daxas® (roflumilast) has recently been launched in the first EU markets and further launches are underway over the coming months. To accelerate the expansion in China, one of the fastest…

Article - 04/02/2013

SYGNIS Pharma - the "new" one: development and commercialisation of molecular diagnostics products

Heidelberg-based SYGNIS Pharma AG is to discontinue its therapeutic R&D projects targeting human nervous system diseases and will in future focus on the research and development of novel molecular biology technologies, including DNA amplification and sequencing as well as drug screening.

Vetters top management team is once again complete. As of June 1st 2008 Peter Soelkner will be heading a number of divisions at the Ravensburg-based company which specialises in the aseptic filling of prefilled injection systems. His new tasks will include Global Key Account Management Corporate Marketing Supply Chain Management and Project Management.

Nycomed agreed with Bayer Schering Pharma on the sale of the preclinical anti-cancer program. The agreement is part of Nycomeds strategic decision not to further invest in oncology RD activities.

Press release - 10/10/2011

Vetter’s state-of-the-art Chicago facility is fully operational

Vetter, a leading contract development and manufacturing organization that specializes in aseptic filling, today announced that its first U.S. facility is now fully operational. Located at the Illinois Science + Technology Park in suburban Chicago, the 24,000-square-foot site includes microbiology and chemical analysis labs, material preparation and compounding functions, three cleanrooms for aseptic filling, and visual inspection. The first to…

European biotech-platform and drug discovery companies will have easier access to Polyclone Bioservices assay design and validation services through its newly announced partnership with Innovendia Consulting from Owingen. EU and national government funded consortia will benefit from the more immediate availability of Polyclones unique combination of in vitro in silico assay design and validation capabilities.